




## Curriculum Vitae

Personal Information	
<b>Title</b>	<b>Dr.</b>
<b>Name</b>	<b>Shintaro Sagami</b>
<b>Degree</b>	<b>MD, PhD</b>
<b>Country</b>	<b>Japan</b>
<b>Affiliation</b>	<b>Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital</b>
	
Educational Background	
Hiroshima University, Hiroshima, Japan	March 23, 2017
● Ph.D., Biomedical and Health Sciences Graduate Program	
Kinki University, Osaka, Japan	March 31, 2007
● M.D., Faculty of Medicine Undergraduate Program	
Professional Experience	
Board Certified Member of the Japanese Society of Internal Medicine	September 14, 2011
Board Certified Gastroenterologist of The Japanese Society of Gastroenterology	January 1, 2014
Designated physician of Japan Intractable Diseases Information Center	December 1, 2014
Board Certified Member of Japan Gastroenterological Endoscopy Society	December 1, 2015
Board Certified Member of Japanese Gastroenterological Association	November 1, 2016
Board Certified Medical instructor of Japanese Gastroenterological Association	November 1, 2016
Fellow of the Japanese Society of Internal Medicine (FJSIM)	December 22, 2017
Infectious disease expert specialist in Japanese Association of Infectious Diseases	January 1, 2018
Councilor of Japan Gastroenterological Endoscopy Society	June 8, 2019
Councilor of Japanese Gastroenterological Association	January 1, 2020
International Bowel Ultrasound Group (IBUS) certification (module 1-3)	July 12, 2021
International Bowel Ultrasound Group EduCum committee member	March 5, 2022
PLOS ONE Academic editor	July 6, 2022
Professional Organizations	
Asian Organization for Crohn's & Colitis (AOCC), European Crohn's and Colitis Organisation (ECCO), American Gastroenterological Association (AGA), Japanese Society for Inflammatory Bowel Disease (JSIBD), The Japanese Society of Gastroenterology, The Japanese Society of Internal Medicine, The Japan Gastroenterological Endoscopy Society (JGES), Japanese Gastroenterological Association (JGA), International Bowel Ultrasound Group (IBUS)	
Main Scientific Publications	
1. Hojo A, Kobayashi T, <b>Sagami S</b> , et al. Usefulness of colestimide for diarrhea in postoperative Crohn's disease. <i>JGH Open</i> 2022; 6 (8):547-553	
2. Okabayashi S, Yamazaki H, <b>Sagami S</b> , et al. Lower effectiveness of intravenous steroid treatment for moderate-to-severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. <i>Aliment Pharmacol Ther.</i> 2022;55(12):1569-1580.	
3. <b>Sagami S.</b> , Kobayashi T, Aihara K, et al. Early improvement in bowel wall thickness on transperineal ultrasonography predicts treatment success in active ulcerative colitis. <i>Aliment Pharmacol Ther</i> 2022. 2022 May;55(10):1320-1329.	
4. <b>Sagami S</b> , Kobayashi T. Editorial: the importance of utilising gastrointestinal ultrasound via transperineal approach in ulcerative colitis-an accurate early predictor of response to treatment. Authors' reply. <i>Aliment Pharmacol Ther.</i> 2022;55(9):1204-1205.	

5. Asonuma K, Kobayashi T, **Sagami S**, et al. Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis. **Inflammatory bowel diseases**. 2022;28(2):200-7.
6. Toyonaga T, Kobayashi T, **Sagami S**, et al. Increased DNA-incorporated thiopurine metabolite as a possible mechanism for leukocytopenia through cell apoptosis in inflammatory bowel disease patients with NUDT15 mutation. **Journal of Gastroenterology** 2021;56(11):999-1007.
7. Morikubo, H., Kobayashi, T., **Sagami, S**, et al. Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition. **J Gastroenterol Hepatol**. 2021;36(8):2116-24.
8. **Sagami S**, T. Kobayashi Y. Allocca R., et al. Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis." **Clin Gastroenterol Hepatol** 2021;19(5): 908-921.e906.
9. **Sagami S**, Nishikawa K, Yamada F, et al. Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan. **J Gastroenterol Hepatol**. 2021;36(8):2091-100.
10. Matsubayashi M, Kobayashi T, **Sagami S**, et al. Determining the usefulness of Capsule Scoring of Ulcerative Colitis in predicting relapse of inactive ulcerative colitis. **J Gastroenterol Hepatol** 2021;36(4):943-50.
11. **Sagami S**, Kobayashi T, and Hibi T. Editorial: transperineal ultrasound in addition to a transabdominal ultrasound in ulcerative colitis-one more arrow in the quiver of non-invasive diagnostics. Authors' reply. **Aliment Pharmacol Ther** 2020, 52(2):403.
12. **Sagami S**, Kobayashi T, Aihara K, et al. Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis." **Aliment Pharmacol Ther** 2020, 51(12): 1373-1383.
13. Higashiyama M, Sugita A, **Sagami S**, et al. Management of elderly ulcerative colitis in Japan. **Journal of gastroenterology** 2019. 54(7):571-586.
14. **Sagami S**, Kobayashi T, Kikkawa N, et al. Combination of colonoscopy and magnetic resonance enterography is more useful for clinical decision making than colonoscopy alone in patients with complicated Crohn's disease. **PLoS One** 2019; 14(2): e0212404.
15. Okabayashi S, Kobayashi T, **Sagami S**, et al. Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis. **Intest Res** 2019; 17(2): 218-226.
16. **Sagami S**, Kobayashi T, Hibi T. Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease. **Inflamm Intest Dis**. 2018; 3(1): 1-10. Epub 2018/12/07.
17. **Sagami S**, Ueno Y, Tanaka S, et al. Choline Deficiency Causes Colonic Type II Natural Killer T (NKT) Cell Loss and Alleviates Murine Colitis under Type I NKT Cell Deficiency. **PLoS ONE** 2017; 12(1): e0169681.
18. **Sagami S**, Ueno Y, Tanaka S, et al. Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study. **Hepatol Res**. 2017;47(9):872-881.
19. Nishiyama S, Oka S, **Sagami S**, et al. Clinical usefulness of narrow band imaging magnifying colonoscopy for assessing ulcerative colitis-associated cancer/dysplasia. **Endosc Int Open**. 2016; 4(11): E1183-E1187.
20. **Sagami S**, Ueno Y, Tanaka S, et al. Successful Use of Adalimumab for Treating Pyoderma Gangrenosum with Ulcerative Colitis under Corticosteroid-tapering Conditions. **Internal medicine**. 2015; 54(17): 2167-72.
21. Onitake T, Ueno Y, **Sagami S**, et al. Pulverized konjac glucomannan ameliorates oxazolone-induced colitis in mice. **European journal of nutrition**. 2015; 54(6): 959-69.
22. Nishiyama S, Oka S, **Sagami S**, et al. Clinical usefulness of endocytoscopy in the remission stage of ulcerative colitis: a pilot study. **Journal of gastroenterology**. 2015; 50(11):1087-93.
23. Hayashi R, Ueno Y, **Sagami S**, et al. Two Cases of Severe Ulcerative Colitis with Colonic Dilatation Resolved with Tacrolimus Therapy. **Case reports in gastroenterology**. 2015; 9(2): 272-7.
24. Hashimoto Y, Amano H, **Sagami S**, et al. Percutaneous transhepatic sclerotherapy for recurrent bleeding ileal varices diagnosed by capsule endoscopy and computed tomography during percutaneous transhepatic venography. **Hepatol Res**. 2013;43(4):436-40.